Pasar al contenido principal

Genetic determinants of neuroimaging brain features (NeuroImaGene)

IJC2020-043216-I

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Incorporación
Convocatoria Juan de la Cierva Incorporación
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIÓ BARCELONABETA BRAIN RESEARCH CENTER

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Genetic characterization of the ALFA study: Uncovering genetic profiles in the Alzheimer's continuum

  • Vilor Tejedor, Natàlia, 1988-
  • Genius, Patricia
  • Rodríguez-Fernández, Blanca
  • Minguillón, Carolina
  • Sadeghi, Iman
  • González Escalante, Armand
  • Crous-Bou, Marta
  • Suárez-Calvet, Marc
  • Grau, Oriol (Grau Rivera)
  • Brugulat Serrat, Anna, 1986-
  • Sánchez Benavides, Gonzalo
  • Esteller, Manel
  • Fauria, Karine
  • Molinuevo, José Luis
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Gispert, Juan Domingo
  • Alzheimer’s Disease Neuroimaging Initiative
  • ALFA Study
Introduction: In 2013, the ALzheimer's and FAmilies (ALFA) project was established to investigate pathophysiological changes in preclinical Alzheimer's disease (AD), and to foster research on early detection and preventive interventions. Methods: We conducted a comprehensive genetic characterization of ALFA participants with respect to neurodegenerative/cerebrovascular diseases, AD biomarkers, brain endophenotypes, risk factors and aging biomarkers. We placed particular emphasis on amyloid/tau status and assessed gender differences. Multiple polygenic risk scores were computed to capture different aspects of genetic predisposition. We additionally compared AD risk in ALFA to that across the full disease spectrum from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Results: Results show that the ALFA project has been successful at establishing a cohort of cognitively unimpaired individuals at high genetic predisposition of AD. Discussion: It is, therefore, well-suited to study early pathophysiological changes in the preclinical AD continuum. Highlights Prevalence of ε4 carriers in ALzheimer and FAmilies (ALFA) is higher than in the general European population The ALFA study is highly enriched in Alzheimer's disease (AD) genetic risk factors beyond APOE AD genetic profiles in ALFA are similar to clinical groups along the continuum ALFA has succeeded in establishing a cohort of cognitively unimpaired individuals at high genetic AD risk ALFA is well suited to study pathogenic events/early pathophysiological changes in AD., The project leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Health Department of the Catalan Government (Health Research and Innovation Strategic Plan (PERIS) 2016-2020 grant# SLT002/16/00201) and the Alzheimer's Association (Grant AARG-19-618265). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under grant no. 2021_SGR_00913. All CRG authors acknowledge the support of the Spanish Ministry of Science, Innovation, and Universities to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. NV-T and OG-R receive funding from the MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR, through the Juan de la Cierva Incorporación Programme (IJC2020-043216-I and IJC2020-043417-I respectively). MS-C receives the support of a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648. The fellowship code is LCF/BQ/PR21/11840004.
Repisalud
Publicación Artículo científico (JournalArticle)

Genetic characterization of the ALFA study: Uncovering genetic profiles in the Alzheimer's continuum.

  • Vilor-Tejedor, Natalia
  • Genius, Patricia
  • Rodríguez-Fernández, Blanca
  • Minguillón, Carolina
  • Sadeghi, Iman
  • González-Escalante, Armand
  • Crous-Bou, Marta
  • Suárez-Calvet, Marc
  • Grau-Rivera, Oriol
  • Brugulat-Serrat, Anna
  • Sánchez-Benavides, Gonzalo
  • Esteller, Manel
  • Fauria, Karine
  • Molinuevo, José Luis
  • Navarro, Arcadi
  • Gispert, Juan Domingo
INTRODUCTION In 2013, the ALzheimer's and FAmilies (ALFA) project was established to investigate pathophysiological changes in preclinical Alzheimer's disease (AD), and to foster research on early detection and preventive interventions. METHODS We conducted a comprehensive genetic characterization of ALFA participants with respect to neurodegenerative/cerebrovascular diseases, AD biomarkers, brain endophenotypes, risk factors and aging biomarkers. We placed particular emphasis on amyloid/tau status and assessed gender differences. Multiple polygenic risk scores were computed to capture different aspects of genetic predisposition. We additionally compared AD risk in ALFA to that across the full disease spectrum from the Alzheimer's Disease Neuroimaging Initiative (ADNI). RESULTS Results show that the ALFA project has been successful at establishing a cohort of cognitively unimpaired individuals at high genetic predisposition of AD. DISCUSSION It is, therefore, well-suited to study early pathophysiological changes in the preclinical AD continuum. Highlights Prevalence of ε4 carriers in ALzheimer and FAmilies (ALFA) is higher than in the general European population The ALFA study is highly enriched in Alzheimer's disease (AD) genetic risk factors beyond APOE AD genetic profiles in ALFA are similar to clinical groups along the continuum ALFA has succeeded in establishing a cohort of cognitively unimpaired individuals at high genetic AD risk ALFA is well suited to study pathogenic events/early pathophysiological changes in AD.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Genetically predicted telomere length and its relationship with neurodegenerative diseases and life expectancy

  • Rodríguez-Fernández, Blanca
  • Gispert, Juan Domingo
  • Guigó, Roderic
  • Navarro, Arcadi
  • Vilor-Tejedor, Natalia
  • Crous-Bou, Marta
Telomere length (TL) is a biomarker of biological aging. Shorter telomeres have been associated with mortality and increased rates of age-related diseases. However, observational studies are unable to conclude whether TL is causally associated with those outcomes. Mendelian randomization (MR) was developed for assessing causality using genetic variants in epidemiological research. The objective of this study was to test the potential causal role of TL in neurodegenerative disorders and life expectancy through MR analysis. Summary level data were extracted from the most recent genome-wide association studies for TL, Alzheimer’s disease (AD), Parkinson’s disease, Frontotemporal dementia, Amyotrophic Lateral Sclerosis, Progressive Supranuclear Palsy and life expectancy. MR estimates revealed that longer telomeres inferred a protective effect on risk of AD (OR = 0.964; adjusted p-value = 0.039). Moreover, longer telomeres were significantly associated with increased life expectancy (βIVW = 0.011; adjusted p-value = 0.039). Sensitivity analyses suggested evidence for directional pleiotropy in AD analyses. Our results showed that genetically predicted longer TL may increase life expectancy and play a protective causal effect on AD. We did not observe significant causal relationships between longer TL and other neurodegenerative diseases. This suggests that the involvement of TL on specific biological mechanisms might differ between AD and life expectancy, with respect to that in other neurodegenerative diseases. Moreover, the presence of pleiotropy may reflect the complex interplay between TL homeostasis and AD pathophysiology. Further observational studies are needed to confirm these results., This project has received funding from the Alzheimer’s Association (Grant AARG-19-618265). JDG is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054) Ministry of Science and Innovation– Spanish State Research Agency. NV-T is funded by a postdoctoral grant, Juan de la Cierva Programme (IJC2020-043216-I).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Genetically predicted telomere length and Alzheimer’s disease endophenotypes: a Mendelian randomization study

  • Rodríguez-Fernández, Blanca
  • Vilor-Tejedor, Natalia
  • Arenaza-Urquijo, Eider M.
  • Sánchez-Benavides, Gonzalo
  • Suárez-Calvet, Marc
  • Operto, Grégory
  • Minguillón, Carolina
  • Fauria, Karine
  • Kollmorgen, Gwendlyn
  • Suridjan, Ivonne
  • Castro de Moura, Manuel
  • Piñeyro, David
  • Esteller, Manel
  • Blennow, Kaj
  • Zetterberg, Henrik
  • De Vivo, Immaculata
  • Molinuevo, José Luis
  • Navarro, Arcadi
  • Gispert, Juan Domingo
  • Sala-Vila, Aleix
  • Crous-Bou, Marta
  • ALFA study
Telomere length (TL) is associated with biological aging, consequently influencing the risk of age-related diseases such as Alzheimer’s disease (AD). We aimed to evaluate the potential causal role of TL in AD endophenotypes (i.e., cognitive performance, N = 2233; brain age and AD-related signatures, N = 1134; and cerebrospinal fluid biomarkers (CSF) of AD and neurodegeneration, N = 304) through a Mendelian randomization (MR) analysis. Our analysis was conducted in the context of the ALFA (ALzheimer and FAmilies) study, a population of cognitively healthy individuals at risk of AD. A total of 20 single nucleotide polymorphisms associated with TL were used to determine the effect of TL on AD endophenotypes. Analyses were adjusted by age, sex, and years of education. Stratified analyses by APOE-ɛ4 status and polygenic risk score of AD were conducted. MR analysis revealed significant associations between genetically predicted longer TL and lower levels of CSF Aβ and higher levels of CSF NfL only in APOE-ɛ4 non-carriers. Moreover, inheriting longer TL was associated with greater cortical thickness in age and AD-related brain signatures and lower levels of CSF p-tau among individuals at a high genetic predisposition to AD. Further observational analyses are warranted to better understand these associations., The project leading to these results has received funding from the Alzheimer’s Association (Grant AARG-19-618265). This project has received funding from Instituto de Salud Carlos III (PI19/00119). Additional support has been received from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007), the Health Department of the Catalan Government (Health Research and Innovation Strategic Plan (PERIS) 2016-2020 grant# SLT002/16/00201), and the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2017-SGR-892. All CRG authors acknowledge the support of the Spanish Ministry of Science, Innovation and Universities to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. NV-T is funded by a post-doctoral grant, Juan de la Cierva Incorporación Programme (IJC2020-043216-I), Ministry of Science and Innovation–Spanish State Research Agency. EMAU is supported by the Spanish Ministry of Science, Innovation and Universities - Spanish State Research Agency (RYC2018-026053-I). MS-C receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement no. 948677). MS-C also receives funding from the Instituto de Salud Carlos III (PI19/00155) and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva Programme grant IJC2018-037478-I). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532); the European Research Council (#681712); Swedish State Support for Clinical Research (#ALFGBG-720931); the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862); the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C); the Olav Thon Foundation; the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2019-0228); the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE); and the UK Dementia Research Institute at UCL. KB is supported by the Swedish Research Council (#2017-00915); the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615); the Swedish Alzheimer Foundation (#AF-742881); Hjärnfonden, Sweden (#FO2017-0243); the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986); the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236); and the National Institute of Health (NIH), USA, (grant #1R01AG068398-01). JDG is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054). AS-V. is the recipient of an Instituto de Salud Carlos III Miguel Servet II fellowship (CP II 17/00029).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Association between telomere length and cognitive function among cognitively unimpaired individuals at risk of Alzheimer's disease

  • Rodríguez-Fernández, Blanca
  • Sánchez-Benavides, Gonzalo
  • Genius, Patricia
  • Minguillón, Carolina
  • Fauria, Karine
  • De Vivo, Immaculata
  • Navarro, Arcadi
  • Molinuevo, Jose Luis
  • Gispert, Juan Domingo
  • Sala-Vila, Aleix
  • Vilor-Tejedor, Natalia
  • Crous-Bou, Marta
[Introduction] Leukocyte telomere length (LTL) is an objective biomarker of biological aging, and it is proposed to play a crucial role in Alzheimer's disease (AD) risk. We aimed at evaluating the cross-sectional association between LTL and cognitive performance in middle-aged cognitively unimpaired individuals at increased risk of AD., [Methods] A total of 1520 participants from the ALFA cohort were included. Relative telomere length was measured in leukocytes through qPCR. LTL was residualized against age and sex, and associations with cognitive performance were assessed in short and long groups based on residualized LTL (rLTL). Interactions with sex and genetic risk of AD were tested., [Results] Non-linear associations were found between LTL and episodic memory (EM). Better EM was associated with longer rLTL among women in the short rLTL group., [Discussion] Results suggest a potential role of telomeres in the cognitive aging process with sex-specific patterns., The project leading to these results has received funding from the Alzheimer’s Association (Grant AARG-19–618265). This project has received funding from Instituto de Salud Carlos III (PI19/00119). Additional support has been received from 'la Caixa' Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17–519007), the Health Department of the Catalan Government (Health Research and Innovation Strategic Plan (PERIS) 2016–2020 grant# SLT002/16/00201), and the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2017-SGR-892. All CRG authors acknowledge the support of the Spanish Ministry of Science, Innovation, and Universities to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme / Generalitat de Catalunya. JDG is supported by the Spanish Ministry of Science and Innovation (RYC-2013–13054). GSB has received funding from the Spanish Ministry of Science and Innovation, Spanish Research Agency (PID2020–119556RA-I00). JDG is supported by the Spanish Ministry of Science and Innovation (RYC-2013–13054). NV-T is funded by the Juan de la Cierva Incorporación Programme (IJC2020–043216-I), Ministry of Science and Innovation– Spanish State Research Agency., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Genetic characterization of the ALFA study: Uncovering genetic profiles in the Alzheimer's continuum

  • Vilor-Tejedor, Natalia
  • Genius, Patricia
  • Rodríguez-Fernández, Blanca
  • Minguillón, Carolina
  • Sadeghi, Iman
  • González-Escalante, Armand
  • Crous-Bou, Marta
  • Suárez-Calvet, Marc
  • Grau-Rivera, Oriol
  • Brugulat-Serrat, Anna
  • Sánchez-Benavides, Gonzalo
  • Esteller, Manel
  • Fauria, Karine
  • Molinuevo, José Luis
  • Navarro, Arcadi
  • Gispert, Juan Domingo
[Introduction] In 2013, the ALzheimer's and FAmilies (ALFA) project was established to investigate pathophysiological changes in preclinical Alzheimer's disease (AD), and to foster research on early detection and preventive interventions., [Methods] We conducted a comprehensive genetic characterization of ALFA participants with respect to neurodegenerative/cerebrovascular diseases, AD biomarkers, brain endophenotypes, risk factors and aging biomarkers. We placed particular emphasis on amyloid/tau status and assessed gender differences. Multiple polygenic risk scores were computed to capture different aspects of genetic predisposition. We additionally compared AD risk in ALFA to that across the full disease spectrum from the Alzheimer's Disease Neuroimaging Initiative (ADNI)., [Results] Results show that the ALFA project has been successful at establishing a cohort of cognitively unimpaired individuals at high genetic predisposition of AD., [Discussion] It is, therefore, well-suited to study early pathophysiological changes in the preclinical AD continuum., The project leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Health Department of the Catalan Government (Health Research and Innovation Strategic Plan (PERIS) 2016-2020 grant# SLT002/16/00201) and the Alzheimer's Association (Grant AARG-19-618265). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under grant no. 2021_SGR_00913. All CRG authors acknowledge the support of the Spanish Ministry of Science, Innovation, and Universities to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. NV-T and OG-R receive funding from the MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR, through the Juan de la Cierva Incorporación Programme (IJC2020-043216-I and IJC2020-043417-I respectively). MS-C receives the support of a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648. The fellowship code is LCF/BQ/PR21/11840004., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Genetic characterization of the ALFA study: Uncovering genetic profiles in the Alzheimer's continuum

  • Vilor Tejedor, Natàlia, 1988-
  • Genius, Patricia
  • Rodríguez-Fernández, Blanca
  • Minguillón, Carolina
  • Sadeghi, Iman
  • González Escalante, Armand
  • Crous-Bou, Marta
  • Suárez-Calvet, Marc
  • Grau, Oriol (Grau Rivera)
  • Brugulat Serrat, Anna, 1986-
  • Sánchez Benavides, Gonzalo
  • Esteller, Manel
  • Fauria, Karine
  • Molinuevo, José Luis
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Gispert, Juan Domingo
  • Alzheimer’s Disease Neuroimaging Initiative
  • ALFA Study
Introduction: In 2013, the ALzheimer's and FAmilies (ALFA) project was established to investigate pathophysiological changes in preclinical Alzheimer's disease (AD), and to foster research on early detection and preventive interventions. Methods: We conducted a comprehensive genetic characterization of ALFA participants with respect to neurodegenerative/cerebrovascular diseases, AD biomarkers, brain endophenotypes, risk factors and aging biomarkers. We placed particular emphasis on amyloid/tau status and assessed gender differences. Multiple polygenic risk scores were computed to capture different aspects of genetic predisposition. We additionally compared AD risk in ALFA to that across the full disease spectrum from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Results: Results show that the ALFA project has been successful at establishing a cohort of cognitively unimpaired individuals at high genetic predisposition of AD. Discussion: It is, therefore, well-suited to study early pathophysiological changes in the preclinical AD continuum. Highlights Prevalence of ε4 carriers in ALzheimer and FAmilies (ALFA) is higher than in the general European population The ALFA study is highly enriched in Alzheimer's disease (AD) genetic risk factors beyond APOE AD genetic profiles in ALFA are similar to clinical groups along the continuum ALFA has succeeded in establishing a cohort of cognitively unimpaired individuals at high genetic AD risk ALFA is well suited to study pathogenic events/early pathophysiological changes in AD., The project leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Health Department of the Catalan Government (Health Research and Innovation Strategic Plan (PERIS) 2016-2020 grant# SLT002/16/00201) and the Alzheimer's Association (Grant AARG-19-618265). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under grant no. 2021_SGR_00913. All CRG authors acknowledge the support of the Spanish Ministry of Science, Innovation, and Universities to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. NV-T and OG-R receive funding from the MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR, through the Juan de la Cierva Incorporación Programme (IJC2020-043216-I and IJC2020-043417-I respectively). MS-C receives the support of a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648. The fellowship code is LCF/BQ/PR21/11840004.